These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29915533)

  • 41. Immunological differences between classical phenothypes of multiple sclerosis.
    Iwanowski P; Losy J
    J Neurol Sci; 2015 Feb; 349(1-2):10-4. PubMed ID: 25586536
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The MRZ reaction in primary progressive multiple sclerosis.
    Hottenrott T; Dersch R; Berger B; Rauer S; Huzly D; Stich O
    Fluids Barriers CNS; 2017 Feb; 14(1):2. PubMed ID: 28166789
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG
    Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identical lesion morphology in primary progressive and relapsing-remitting MS--an ultrahigh field MRI study.
    Kuchling J; Ramien C; Bozin I; Dörr J; Harms L; Rosche B; Niendorf T; Paul F; Sinnecker T; Wuerfel J
    Mult Scler; 2014 Dec; 20(14):1866-71. PubMed ID: 24781284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Late onset multiple sclerosis: Is it really late onset?
    Roohani P; Emiru T; Carpenter A; Luzzio C; Freeman J; Scarberry S; Beaver G; Davidson L; Parry G
    Mult Scler Relat Disord; 2014 Jul; 3(4):444-9. PubMed ID: 25877055
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.
    Komori M; Matsuyama Y; Nirasawa T; Thiele H; Becker M; Alexandrov T; Saida T; Tanaka M; Matsuo H; Tomimoto H; Takahashi R; Tashiro K; Ikegawa M; Kondo T
    Ann Neurol; 2012 May; 71(5):614-23. PubMed ID: 22522477
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Global transcriptome profiling of mild relapsing-remitting versus primary progressive multiple sclerosis.
    Koch MW; Ilnytskyy Y; Golubov A; Metz LM; Yong VW; Kovalchuk O
    Eur J Neurol; 2018 Apr; 25(4):651-658. PubMed ID: 29316044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary progressive versus relapsing remitting multiple sclerosis in Japanese patients: a combined clinical, magnetic resonance imaging and multimodality evoked potential study.
    Kira J; Tobimatsu S; Goto I; Hasuo K
    J Neurol Sci; 1993 Jul; 117(1-2):179-85. PubMed ID: 8410054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
    Antel J; Antel S; Caramanos Z; Arnold DL; Kuhlmann T
    Acta Neuropathol; 2012 May; 123(5):627-38. PubMed ID: 22327362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review.
    McKay KA; Kwan V; Duggan T; Tremlett H
    Biomed Res Int; 2015; 2015():817238. PubMed ID: 25802867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS.
    Mills EA; Begay JA; Fisher C; Mao-Draayer Y
    Mult Scler; 2018 Dec; 24(14):1795-1807. PubMed ID: 30303445
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolomic alterations associated with Kallmann syndrome.
    Guo Y; Li X; Yan S; Li Y
    Ann Transl Med; 2020 Apr; 8(8):529. PubMed ID: 32411752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progression rates and sample size estimates for PPMS based on the CLIMB study population.
    Raghavan K; Healy BC; Carruthers RL; Chitnis T
    Mult Scler; 2015 Feb; 21(2):180-8. PubMed ID: 25070676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms.
    Aeinehband S; Brenner P; Ståhl S; Bhat M; Fidock MD; Khademi M; Olsson T; Engberg G; Jokinen J; Erhardt S; Piehl F
    Brain Behav Immun; 2016 Jan; 51():47-55. PubMed ID: 26189678
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disease-Modifying Treatment in Progressive Multiple Sclerosis.
    Ciotti JR; Cross AH
    Curr Treat Options Neurol; 2018 Apr; 20(5):12. PubMed ID: 29627873
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
    Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
    Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis.
    Lassmann H
    Front Immunol; 2018; 9():3116. PubMed ID: 30687321
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
    Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
    Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Income in Multiple Sclerosis Patients with Different Disease Phenotypes.
    Kavaliunas A; Manouchehrinia A; Danylaite Karrenbauer V; Gyllensten H; Glaser A; Alexanderson K; Hillert J
    PLoS One; 2017; 12(1):e0169460. PubMed ID: 28081163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.